Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biophytis ADR Representing 4000 Ord Shs BPTSY

Healthcare Biotechnology
Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The Company is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory... see more

Recent & Breaking News (OTCPK:BPTSY)

Biophytis Receives Notice of Delisting From Nasdaq and Announces It Will Request a Hearing Before the Nasdaq Hearings Panel

Accesswire October 27, 2023

Biophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its Operations

Accesswire September 27, 2023

Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)

Accesswire September 25, 2023

Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19

Accesswire September 19, 2023

Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer

Accesswire September 14, 2023

Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia

Accesswire September 11, 2023

Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York

Accesswire September 4, 2023

Biophytis Announces Next Regulatory Steps in Europe and the United States for its COVA Project

Accesswire August 16, 2023

Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe

Accesswire August 8, 2023

Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19

Accesswire July 20, 2023

Biophytis Announces $3.8 Million Registered Direct Offering

Accesswire July 19, 2023

Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound

Accesswire July 18, 2023

Biophytis Has Filed with The FDA For Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia

Accesswire July 10, 2023

Biophytis Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress

Accesswire June 19, 2023

Biophytis: Results of the Annual General Meeting on June 16, 2023 All Resolutions Presented by the Company Have Been Adopted

Accesswire June 16, 2023

Biophytis to Participate at the BIO International Convention in Boston from the 5th to the 8th of June

Accesswire June 5, 2023

Biophytis has Filed with the French National Authority for Health (HAS) an Application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19

Accesswire May 26, 2023

Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference

Accesswire May 25, 2023

Biophytis has Filed with the EMA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia

Accesswire May 15, 2023

Successful Capital Increase for Biophytis with €2.3 million Raised

Accesswire May 11, 2023